Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders
| Autor: | Luiz Gustavo Piccoli de Melo, George M. Anderson, Sandra Odebrecht Vargas Nunes, Décio Sabbattini Barbosa, Michael Maes, André F. Carvalho, Piotr Gałecki, Heber Odebrecht Vargas |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Bipolar Disorder Inflammation medicine.disease_cause 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Insulin resistance Immune system Internal medicine medicine Humans Biological Psychiatry Pharmacology Metabolic Syndrome Depressive Disorder Major Cholesterol medicine.disease Comorbidity 030227 psychiatry Oxidative Stress Endocrinology Mood disorders chemistry Nitrosative Stress Immunology medicine.symptom Metabolic syndrome Psychology 030217 neurology & neurosurgery Oxidative stress |
| Zdroj: | Progress in neuro-psychopharmacologybiological psychiatry. 78 |
| ISSN: | 1878-4216 |
| Popis: | This review examines the shared immune-inflammatory, oxidative and nitrosative stress (IONS) and metabolic pathways underpinning metabolic syndrome (MetS), bipolar disorder (BD) and major depressive disorder (MDD). Shared pathways in both MetS and mood disorders are low grade inflammation, including increased levels of pro-inflammatory cytokines and acute phase proteins, increased lipid peroxidation with formation of malondialdehyde and oxidized low density lipoprotein cholesterol (LDL-c), hypernitrosylation, lowered levels of antioxidants, most importantly zinc and paraoxonase (PON1), increased bacterial translocation (leaky gut), increased atherogenic index of plasma and Castelli risk indices; and reduced levels of high-density lipoprotein (HDL-c) cholesterol. Insulin resistance is probably not a major factor associated with mood disorders. Given the high levels of IONS and metabolic dysregulation in BD and MDD and the high comorbidity with the atherogenic components of the MetS, mood disorders should be viewed as systemic neuro-IONS-metabolic disorders. The IONS-metabolic biomarkers may have prognostic value and may contribute to the development of novel treatments targeting neuro-immune, neuro-oxidative and neuro-nitrosative pathways. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect